MarketPulse

palbociclib

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Celcuity Inc.

Celcuity's Gedatolisib Shows 76% Risk Reduction in Breast Cancer Trial

Celcuity's gedatolisib achieved 76% risk reduction in advanced breast cancer with PIK3CA wild-type mutations; FDA Priority Review decision expected July 2026.
CELCPhase 3 trialprogression-free survival
BenzingaBenzinga··Vandana Singh

Roche's Breast Cancer Drug Falls Short in Pivotal Trial, Stock Drops 5%

Roche's giredestrant failed to meet primary endpoint in Phase 3 breast cancer trial, causing 5% stock decline. Company plans adjuvant trial readout in 2027.
LLYNVORHHBYclinical trial failurePhase 3 trial